Rep. Jefferson Shreve Purchases Shares of Edwards Lifesciences Co. (NYSE:EW)

Posted by Bonnie Powley on May 12th, 2025

Representative Jefferson Shreve (R-Indiana) recently bought shares of Edwards Lifesciences Co. (NYSE:EW). In a filing disclosed on May 08th, the Representative disclosed that they had bought between $15,001 and $50,000 in Edwards Lifesciences stock on April 7th. The trade occurred in the Representative’s “CRT – STANDARD UNIT TRUST” account.

Representative Jefferson Shreve also recently made the following trade(s):

Purchased $50,001 – $100,000 in shares of Chipotle Mexican Grill (NYSE:CMG) on 4/17/2025.
Purchased $50,001 – $100,000 in shares of Applied Materials (NASDAQ:AMAT) on 4/17/2025.
Purchased $15,001 – $50,000 in shares of Caterpillar (NYSE:CAT) on 4/17/2025.
Sold $15,001 – $50,000 in shares of Lululemon Athletica (NASDAQ:LULU) on 4/17/2025.
Purchased $15,001 – $50,000 in shares of Western Digital (NASDAQ:WDC) on 4/17/2025.
Sold $15,001 – $50,000 in shares of Zoetis (NYSE:ZTS) on 4/17/2025.
Purchased $15,001 – $50,000 in shares of Stryker (NYSE:SYK) on 4/17/2025.
Purchased $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 4/17/2025.
Purchased $15,001 – $50,000 in shares of CSX (NASDAQ:CSX) on 4/17/2025.
Purchased $15,001 – $50,000 in shares of Ross Stores (NASDAQ:ROST) on 4/17/2025.

Edwards Lifesciences Trading Down 1.1%

NYSE EW opened at $73.82 on Monday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company has a fifty day simple moving average of $71.48 and a two-hundred day simple moving average of $71.51. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $95.25. The stock has a market cap of $43.40 billion, a P/E ratio of 10.59, a P/E/G ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The firm had revenue of $1.41 billion during the quarter, compared to analysts’ expectations of $1.40 billion. During the same quarter last year, the company posted $0.66 earnings per share. The firm’s revenue was up 6.2% compared to the same quarter last year. On average, analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Wall Street Analyst Weigh In

EW has been the subject of several recent research reports. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their target price for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Barclays raised their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Canaccord Genuity Group raised their target price on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the stock a “hold” rating in a report on Friday, April 25th. Morgan Stanley raised their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 12th. Finally, Truist Financial dropped their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $79.45.

Read Our Latest Stock Report on EW

Institutional Trading of Edwards Lifesciences

Institutional investors have recently modified their holdings of the stock. Norges Bank acquired a new position in Edwards Lifesciences during the fourth quarter worth about $610,895,000. Jennison Associates LLC acquired a new position in Edwards Lifesciences during the fourth quarter worth about $555,939,000. Vanguard Group Inc. boosted its position in Edwards Lifesciences by 10.4% during the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock worth $5,117,845,000 after acquiring an additional 6,537,494 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in Edwards Lifesciences by 475.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock worth $314,182,000 after acquiring an additional 3,506,886 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Edwards Lifesciences during the fourth quarter worth about $213,844,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction dated Friday, May 9th. The shares were sold at an average price of $74.40, for a total transaction of $837,000.00. Following the transaction, the chief financial officer now directly owns 41,098 shares of the company’s stock, valued at $3,057,691.20. The trade was a 21.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.75, for a total transaction of $492,375.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,555,402. This trade represents a 12.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 89,681 shares of company stock worth $6,492,703. 1.29% of the stock is owned by insiders.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana’s 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana’s 6th Congressional District. He declared candidacy for the 2026 election.

Email [email protected] to notify us of updates to this biography.
Jefferson Shreve earned a bachelor’s degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve’s career experience includes working as a real estate executive.

Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

Edwards Lifesciences Company Profile

(Get Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.